优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月

证券日报
Yesterday

9月14日,国际肺癌研究协会2026世界肺癌大会正在召开。会上,阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。研究显示,优赫得(注射用德曲妥珠单抗)一线治疗不可切除的局部晚期或转移性HER2突变非鳞状非小细胞肺癌(NSCLC)患者,与全球标准治疗方案(铂类-培美曲塞双药化疗联合帕博利珠单抗)相比,在无进展生存期(PFS)方面取得了具有统计学意义和临床意义的改善。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10